Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup.